Stay updated on PRIMMO Clinical Trial
Sign up to get notified when there's something new on the PRIMMO Clinical Trial page.

Latest updates to the PRIMMO Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe record presents details of the completed Phase II PRIMMO trial of pembrolizumab, radiation, and an immunomodulatory cocktail for cervical and uterine cancers, including its design, eligibility criteria, outcome measures, and Belgian locations. It also includes study collaborators, publications, and record dates.SummaryDifference59%

- Check18 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the study record remains inaccessible behind a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner was added announcing NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and linking to related updates. The study record still displays a 403 Forbidden error.SummaryDifference1%

- Check32 days agoChange DetectedThe footer now displays site revision v3.7.2 instead of v3.7.1. The study record page continues to show a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study content with an access-denied message. The study details are no longer accessible on this page.SummaryDifference20%

Stay in the know with updates to PRIMMO Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRIMMO Clinical Trial page.